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AbstrACt
Objectives Approximately one in eight practices in 
primary care in England are ‘dispensing practices’ with 
an in-house dispensary providing medication directly to 
patients. These practices can generate additional income 
by negotiating lower prices on higher cost drugs, while 
being reimbursed at a standard rate. They, therefore, have 
a potential financial conflict of interest around prescribing 
choices. We aimed to determine whether dispensing 
practices are more likely to prescribe high-cost options for 
four commonly prescribed classes of drug where there is 
no evidence of superiority for high-cost options.
Design A list was generated of drugs with high acquisition 
costs that were no more clinically effective than those 
with the lowest acquisition costs, for all four classes 
of drug examined. Data were obtained prescribing of 
statins, proton pump inhibitors (PPIs), angiotensin receptor 
blockers (ARBs) and ACE inhibitors (ACEis). Logistic 
regression was used to calculate ORs for prescribing high-
cost options in dispensing practices, adjusting for Index 
of Multiple Deprivation score, practice list size and the 
number of doctors at each practice.
setting English primary care.
Participants All general practices in England.
Main outcome measures Mean cost per dose was 
calculated separately for dispensing and non-dispensing 
practices. Dispensing practices can vary in the number 
of patients they dispense to; we, therefore, additionally 
compared practices with no dispensing patients, low, 
medium and high proportions of dispensing patients. Total 
cost savings were modelled by applying the mean cost 
per dose from non-dispensing practices to the number of 
doses prescribed in dispensing practices.
results Dispensing practices were more likely to 
prescribe high-cost drugs across all classes: statins 
adjusted OR 1.51 (95% CI 1.49 to 1.53, p<0.0001), PPIs 
OR 1.11 (95% CI 1.09 to 1.13, p<0.0001), ACEi OR 2.58 
(95% CI 2.46 to 2.70, p<0.0001), ARB OR 5.11 (95% CI 
5.02 to 5.20, p<0.0001). Mean cost per dose in pence was 
higher in dispensing practices (statins 7.44 vs 6.27, PPIs 
5.57 vs 5.46, ACEi 4.30 vs 4.24, ARB 11.09 vs 8.19). For 
all drug classes, the more dispensing patients a practice 
had, the more likely it was to issue a prescription for a 
high-cost option. Total cost savings in England available 
from all four classes are £628 875 per month or £7 546 
502 per year.
Conclusions Doctors in dispensing practices are more 
likely to prescribe higher cost drugs. This is the largest 
study ever conducted on dispensing practices, and the 
first contemporary research suggesting some UK doctors 
respond to a financial conflict of interest in treatment 
decisions. The reimbursement system for dispensing 
practices may generate unintended consequences. Robust 
routine audit of practices prescribing higher volumes of 
unnecessarily expensive drugs may help reduce costs.
bACkgrOunD 
Approximately one in eight practices in 
English National Health Service (NHS) 
primary care are ‘dispensing practices’, with 
an in-house dispensary. These practices are 
generally found in rural areas that have fewer 
pharmacies, and help provide convenient 
access to medicines for patients. However, 
doctors working in dispensing practices 
have a potential financial conflict of interest 
around their prescribing decisions, because 
strengths and limitations of this study
 ► We found a substantial effect size, which was 
present across four broad categories of high-cost 
prescribing.
 ► We were able to measure prescribing for the whole 
of England, eliminating selection bias.
 ► We were able to use demographic data to adjust for 
potential confounding factors, such as practice list 
size and deprivation.
 ► Though we prespecified the list of high-cost and 
low-cost options created for the logistic regression, 
we feel these choices reflect the high-cost and low-
cost options available. This list is available online.
 ► We were unable to determine a causal relationship, 
given the cross-sectional design of the study.
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they have the opportunity to earn additional practice 
revenue by prescribing higher cost drugs. This arises 
because the dispensary arm of such practices can purchase 
high-cost branded drugs at a discount, when procuring 
large quantities of commonly used treatments, but they 
continue to receive reimbursement from the NHS at a 
flat rate which is pegged to the standard non-discounted 
cost of a drug.1 Drugs with lower acquisition costs present 
less opportunity for profit. When a general practitioner 
(GP) prescribes a drug generically reimbursement is 
usually based on the Drug Tariff generic price, although 
the dispensing contractor can supply either a generic 
or branded product against that prescription. However, 
when the prescription is written for a branded prepara-
tion, the dispensing contractor must supply that brand, 
and is reimbursed accordingly. There is no opportunity 
for generic substitution in the NHS in England.
There is an extensive literature suggesting that, like 
other people, the choices of doctors can be affected by 
their financial interests.2–4 A 2009 systematic review exam-
ined whether doctors with a dispensing role exhibited 
different prescribing behaviour in a wide range of settings 
including Zimbabwe, South Korea, Taiwan and the UK in 
the 1990s.5 The review found studies measuring a range 
of outcomes. Many of these studies refer to outdated or 
unusual health system configurations, such as settings 
with minimal controls around prescribed drugs, and the 
largest studies compared only a few tens of practices, a 
few hundred patient records or a few tens of thousands 
of prescriptions.
We set out to examine whether NHS doctors in English 
dispensing practices have different prescribing behaviour 
to non-dispensing practices. We used modern computa-
tional methods on a very large quantity of highly gran-
ular contemporary national data. Our objectives were to 
establish whether dispensing practices were more likely to 
prescribe more expensive drugs in place of cheaper and 
equally effective drugs, using fair comparisons where there 
were no grounds to expect a difference between rural and 
urban areas. We focused on commonly prescribed treat-
ments where the difference in cost was large (rather than 
prescriptions of very high-cost items that are infrequently 
prescribed) because this is where the potential conflict 
of interest is greatest, as discounted purchases on higher 
cost drugs can be arranged by dispensing practices when 
purchasing larger quantities of drugs.
MethODs
Data preparation
Prescribing data for each practice were obtained from 
the Health and Social Care Information Centre (HSCIC) 
NHS England Primary Care Prescribing dataset6 for all 
prescriptions dispensed by all NHS dispensing contrac-
tors, including pharmacies and dispensing practices, 
submitted for payment to the NHS Business Services 
Authority (NHSBSA) for January 2015. The data were 
imported into Google BigQuery.7 Data were extracted at 
‘presentation’ level, which in the context of prescribing 
data means the actual product prescribed by the doctor, 
including the identity of the specific branded or ‘branded 
generic’ product (where specified) rather than simply 
the chemical name. Prescribing costs for each product in 
each practice were calculated using the ‘actual cost’ field 
in the HSCIC data, which is the cost to the NHS. The 
identity of each practice’s clinical commissioning group 
(CCG) was also imported from this dataset.
A list of dispensing practices covering January 2015 was 
downloaded from the NHSBSA website8 and matched 
onto the prescribing data. This dataset gives the number 
of dispensing and non-dispensing patients in each GP 
practice. Practices are not only ‘dispensing’ or ‘non-dis-
pensing’ practices: each dispensing practice may serve 
a range of patients, with some ‘dispensing patients’ 
who live in areas without adequate pharmacy provision 
and receive both medical and dispensing services; and 
some ‘non-dispensing patients’ who receive only medical 
services. For each practice, the proportion of dispensing 
patients was calculated and converted into both a binary 
variable (no dispensing patients, any dispensing patients) 
and an ordinal categorical variable with arbitrary prespec-
ified cut points at 0.000001%, 35% and 70%. These data 
also include a binary ‘GP practice’ field. This was used to 
drop all non-standard practices (including out of hours 
services, community health services, prisons and home-
less clinics) from the dataset, leaving only data from stan-
dard GP settings.
We also imported demographic data on Index of 
Multiple Deprivation (IMD) score (from Public Health 
England), practice list size (from NHS Digital) and the 
number of doctors at each practice (from NHS Digital), 
to be used to adjust for confounding in multivariable 
models.
A two-way table was created for each analysis, where 
each row contained data on a single practice with columns 
for practice identification code and name; CCG identi-
fication code; the number of dispensing patients and 
the total number of patients; dispensing status; ordinal 
dispensing status; total items dispensed, total quantity 
dispensed and total cost for the high-cost drugs; and 
total items dispensed, total quantity dispensed and total 
cost for the lower cost drugs. In this dataset, an ‘item’ is 
a presentation appearing on a prescription, while ‘quan-
tity’ is the number of doses issued.
high-cost and low-cost drugs
We examined prescribing data on statins, proton pump 
inhibitors (PPIs), ACE inhibitors (ACEis) and angio-
tensin receptor blockers (ARBs) as these are the four 
most commonly prescribed classes of drugs by prescrip-
tion items from NHS England prescribing data where 
there is clear guidance that higher cost items are no more 
effective than lower cost items. Within each of these four 
classes, we identified options with a high acquisition cost 
which are considered to be as effective as those with the 
lowest acquisition cost,9–12 in discussion with colleagues 
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in clinical pharmacology, medicines optimisation and 
evidence-based medicine. This included not just branded 
versions of generic drugs (such as Lipitor in place of 
generic atorvastatin), but also different drugs in the same 
class that are widely held to be equally effective (such as 
rosuvastatin in place of atorvastatin). These are known 
as ‘generic substitutions’ and ‘therapeutic substitutions’, 
respectively.13 The lower cost options are not held to be 
universally clinically preferable, with an ideal prescribing 
rate for the expensive options of zero, because some indi-
vidual patients may benefit from a different choice of drug 
within a class on the grounds of idiosyncratic side effects 
or treatment response. However, there are no a priori 
grounds to believe that such patients would be differen-
tially distributed among dispensing and non-dispensing 
practices. By taking the proportion of prescriptions for 
each class, which were for high-cost options, we, there-
fore, controlled for a patient need for the total volume of 
prescribing for each clinical indication.
The lists of drugs and drug presentations (ie, brands) 
coded as high-cost or low-cost are in table 1, and the full 
British National Formulary and HSCIC prescribing data 
code lists are available on GitHub14 to facilitate reproduc-
ibility. This list was generated with a senior pharmacist 
(RC) prior to conducting the low-cost versus high-cost 
analysis. Drugs and presentations were manually coded as 
low and high cost, because it is incorrect to assume that 
generic products are always low cost, and branded prod-
ucts high-cost: when a chemical comes out of patent, the 
price of the branded item often falls in line with cheaper 
generic entrants to the market; while generic options may 
be manufactured for drugs before they come out of patent 
(under agreement from the patent holder) at similarly 
high prices to the branded product. Where a drug was out 
of patent, and a branded version continued to be avail-
able alongside generic options, but its price was compa-
rable to the generic options, then that low-cost branded 
version was included in the low-cost list. Where a branded 
option continued to be available after patent expiry but 
was more than three times the cost of the generic option, 
it was counted as a higher cost branded option. These 
high-cost branded off-patent drugs are specifically iden-
tified in table 1 by brand name alongside the drugs that 
remain entirely under patent. (For clarity: perindopril 
arginine is a branded product currently under patent, 
while perindopril erbumine is now off-patent and avail-
able in low-cost generic formulations).
Data analysis
Data were imported into Stata V.1415 for analysis by logistic 
regression. Although the NHS England dataset contains 
only aggregated numbers of prescriptions for each prac-
tice, each prescription in each practice in each class was 
analysed as a single prescribing choice for each patient—
to either give a high-cost or low-cost drug—as it is highly 
unlikely that any patients were prescribed two members 
of the same class of drug simultaneously. For each class 
of drug, we calculated ORs for prescribing a high-cost 
option in dispensing and non-dispensing practices using 
logistic regression. We then repeated this analysis using 
the ordinal categorical variable for dispensing status to 
assess whether there was a ‘dose–response’ relationship 
between the proportion of dispensing patients in a prac-
tice and the odds of prescribing a high-cost option. For 
both logistic regression models, above, we also created 
multivariable models, adjusting for IMDs, practice list size 
and the number of doctors in each practice.
For each class of drug, the mean cost per prescription 
was calculated, separately for dispensing practices and 
non-dispensing practices, by aggregating the cost of all 
prescriptions issued and dividing this by the number of 
doses issued. This was calculated by dose, rather than by 
prescription, as the number of doses per prescription 
can vary. This was repeated for each ordinal category 
of dispensing practices. Since only 13% of all practices 
in England are dispensing practices, we also calculated 
the proportion of dispensing practices in the top 10 
and top 100 highest prescribers of high-cost options, to 
Table 1 List of higher and lower cost options in each class
Class Higher cost options Lower cost options
Statins Rosuvastatin (all), Crestor, Atorvastatin 30 mg and 
60 mg, Lipitor, Fluvastatin 80 mg M/R tabs, Lescol 
capsules, Luvinsta XL, Dorisin XL, Lipostat, Zocor.
Atorvastatin 10/20/40/80 mg tabs, Fluvastatin caps, 
Pravastatin, Simvastatin, Simvador (low-cost branded 
option).
Proton pump 
inhibitor 
Nexium, Zoton Cap 30 mg E/C Gran, Omeprazole 
E/C tabs, Losec caps, Losec dispersible, Omeran, 
Zanprol, Mezzopram, Protium, Pantoloc, Pariet.
Esomeprazole, Emozul, Lansoprazole, Zoton FasTab, 
Omeprazole caps, Mepradec Caps, Pantoprazole, 
Rabeprazole.
ACE inhibitor Perindopril tosilate, Moexipril, Perdix, Cilazapril, 
Vascace, Captopril capsules, Capoten tab 25 mg, 
Innovace, Zestril, Coversyl, Accupro 20/40 mg, 
Quinil 20/40 mg, Tritace, Imidapril, Tanatril, 
Perindopril arginine, Coversyl arginine.
Captopril, Enalapril, Fosinopril, Staril, Lisinopril, 
Perindopril erbumine, Quinapril, Accupro 5/10 mg, 
Quinil 5/10 mg, Ramipril, Trandolapril, Gopten.
Angiotensin 
receptor blocker 
Azilsartan, Edarbi, Olmesartan, Olmetec, Amias, 
Aprovel, Cozaar, Micardis, Tolura, Diovan, 
Eprosartan, Teveten.
Candesartan cilexet, Irbesartan, Losartan, Telmisartan, 
Valsartan.
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explore whether dispensing practices were more likely 
to be among the highest prescribers of high-cost options 
nationally.
Lastly, we modelled cost savings available in England 
if dispensing practices were to prescribe drugs with the 
same mean cost per dose as non-dispensing practices. 
The mean cost per dose of non-dispensing practices was 
multiplied by the total number of doses prescribed in 
each dispensing practice, to calculate the modelled total 
cost for that class of drugs, and this was subtracted from 
the actual total cost, for all dispensing practices.
Patient and public involvement
No patients were involved in setting the research question 
or the outcome measures, nor were they involved in the 
design or conduct of the study. No patients were asked to 
advise on the interpretation or writing up of results. There 
are no plans to disseminate the results of the research to 
study participants.
results
All data were imported successfully. Only standard GP 
practices were analysed, therefore, 2863 non-standard 
prescribing settings in the same dataset were dropped 
(this included out of hours services, community health 
services, prisons and homeless clinics). Data for 7836 
practices with a mean patient list of 7258 people were 
analysed in 211 CCGs, each containing between 1 and 
123 practices. In total, the data for the month covered 15 
060 963 items (with a total cost of £30 862 027). The odds 
ratios for prescriptions from the high-cost or low-cost list 
are presented in table 2, alongside the percentage of all 
prescriptions that were for high-cost options in dispensing 
and non-dispensing practices, the mean price per dose 
for prescriptions issued in dispensing and non-dispensing 
practices, and the total number of prescriptions issued in 
England. From this, it can be seen that dispensing prac-
tices are significantly more likely to prescribe drugs from 
the list of higher cost products across all four categories: 
statins OR 1.66 (95% CI 1.64 to 1.68, p<0.0001), PPI OR 
1.14 (95% CI 1.12 to 1.17, p<0.0001), ACEi OR 2.42 (95% 
CI 2.32 to 2.52, p<0.0001), ARB OR 4.79 (95% CI 4.72 
to 4.87, p<0.0001). Similar odds ratios are observed after 
adjusting for IMD, practice list size and number of GPs 
(table 2).
The OR for prescription of a high-cost option by an 
increasing proportion of dispensing patients is presented 
in table 3. From this, it can be seen that there is a consis-
tent pattern for higher odds of high-cost prescribing 
the more dispensing patients a practice has, across all 
four classes of drug. Again, there is little difference in 
ORs between the univariable and multivariable models. 
A similar pattern is seen for the mean cost per dose in 
table 4.
Dispensing practices make up only 13% of all prac-
tices overall. Table 5 shows the proportion of dispensing T
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practices in the top 10 and 100 highest prescribers of 
high-cost drugs, for each of the four classes of drug; and 
the percentage of all prescriptions that are for high-
cost drugs in the top 10 and top 100 highest prescribers 
of high-cost drugs. For all classes of drug, except PPIs, 
dispensing practices appear to be over-represented 
among the highest prescribers of high-cost drugs.
The cost savings for the NHS in England that would 
accrue if dispensing practices prescribed drugs with the 
same prices as non-dispensing practices are presented in 
table 6, with savings per month and savings per year for 
each class. Total cost savings available are £628 875 per 
month or £7 546 497 per year, which represents 2.04% of 
total expenditure on these classes of drug.
DisCussiOn
summary
We found that doctors in England rarely prescribe high-
cost drugs where there are equally effective low-cost 
alternatives, but that doctors with a potential financial 
conflict of interest through working in a dispensing prac-
tice are significantly more likely to prescribe high-cost 
options, for four commonly prescribed classes of drug. 
Total cost savings available, if doctors in dispensing prac-
tices were to prescribe drugs at the same price as doctors 
in non-dispensing practices, are £7 546 502 per year.
strengths and weaknesses
This is the first contemporary study of conflict of interest 
in English doctors’ prescribing decisions. It is also the 
largest study to date of dispensing practices’ prescribing 
behaviour, by several orders of magnitude, both in terms 
of a number of prescribing decisions and the number of 
practices covered; it is also the first to use chemical and 
presentation-level data.
A key strength of our study design is the ability to control 
for confounding caused by different populations covered 
by each class of practice. There are good grounds to 
believe that the patient population covered by dispensing 
Table 3 ORs for prescribing high-cost drugs by category of dispensing practice
Drug
Proportion of 
dispensing patients
Univariable
Adjusted for Index of Multiple 
Deprivation, practice list size 
and no of GPs
OR 95% CI OR 95% CI
Statins 0 Reference Reference
>0%–35% 1.46 (1.43 to 1.48) 1.35 (1.32 to 1.37)
35%–70% 1.79 (1.76 to 1.82) 1.62 (1.59 to 1.65)
70%–100% 2.02 (1.98 to 2.06) 1.79 (1.75 to 1.84)
Proton pump inhibitor 0 Reference Reference
>0%–35% 1.11 (1.08 to 1.14) 1.08 (1.05 to 1.11)
35%–70% 1.12 (1.08 to 1.15) 1.08 (1.05 to 1.12)
70%–100% 1.31 (1.26 to 1.37) 1.27 (1.21 to 1.32)
ACE inhibitor 0 Reference Reference
>0%–35% 1.58 (1.48 to 1.68) 1.80 (1.68 to 1.92)
35%–70% 3.05 (2.89 to 3.22) 3.28 (3.09 to 3.48)
70%–100% 3.65 (3.40 to 3.91) 3.37 (3.12 to 3.64)
Angiotensin receptor blocker 0 Reference Reference
>0%–35% 4.28 (4.20 to 4.36) 4.60 (4.51 to 4.70)
35%–70% 5.33 (5.22 to 5.44) 5.67 (5.54 to 5.80)
70%–100% 5.20 (5.06 to 5.34) 5.50 (5.34 to 5.67)
Table 4 Mean cost per dose by category of dispensing practice
Mean cost per dose in pence (95% CI)
0 dispensing patients
>0%–35% dispensing 
patients
35%–70% dispensing 
patients
70%–100% dispensing 
patients
Statins 6.27 (6.23 to 6.31) 6.89 (6.72 to 7.06) 7.65 (7.35 to 7.94) 8.05 (7.59 to8.5)
Proton pump inhibitor 5.46 (5.44 to 5.49) 5.47 (5.41 to 5.53) 5.61 (5.53 to 5.68) 5.69 (5.57 to 5.8)
ACE inhibitor 4.24 (4.23 to 4.25) 4.30 (4.17 to 4.43) 4.29 (4.18 to 4.4) 4.30 (4.11 to 4.49)
Angiotensin receptor blocker 8.19 (8.13 to 8.24) 10.42 (9.91 to 10.94) 11.63 (10.95 to 12.32) 11.48 (10.67 to 12.3)
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practices, which is predominantly rural, may be systemat-
ically different to non-dispensing practices with respect 
to social class, smoking, age, and other demographic and 
health measures. By examining prescriptions of high-cost 
branded drugs as a proportion of total prescriptions for 
that class of drug, the design of our study accounts for any 
confounding caused by the differential need for a given 
drug class in areas covered by dispensing or non-dis-
pensing practices. We additionally adjusted for factors 
such as deprivation score and practice size to ensure they 
were not responsible for confounding, and found the 
multivariable results to be extremely similar. There are no 
a priori reasons to believe that any supposed clinical need 
for higher cost options for these four classes of drug is 
differentially distributed between dispensing and non-dis-
pensing practice catchment areas.
One weakness of our study is that the members of each 
prespecified list of high-cost and low-cost options created 
for the logistic regression could be contested. However, 
the finding that the overall mean cost per dose in each 
drug class is higher in dispensing practices is not depen-
dent on these choices; and we have shared all analytical 
code, data and lists of drug identifiers, so that others can 
perform their own sensitivity analyses with alternative lists 
of drugs should they wish. Another weakness is that, given 
the cross-sectional design of the study, we are unable to 
determine a causal relationship.
Context of other work
Previous work on smaller cohorts in different settings 
has found that doctors working in dispensing practices 
have different prescribing behaviours to those in non-dis-
pensing settings.5 For example, a 2002 study of 57 doctors 
in Zimbabwe16 found that dispensing doctors prescribed 
more drugs per patient, injected more patients and 
prescribed more antibiotics, with no difference in use of 
generics; in South Korea a range of regulatory changes 
in 2000, including greater separation of pharmacists’ and 
doctors’ roles, was associated with a reduction in prescrip-
tions for peptic ulcer drugs17 and antibiotics.18 Recent 
work has been more limited. An Australian study from 
2011 examined the only total number of prescriptions 
issued, in 2005–2007 data, and found that dispensing 
doctors issued fewer prescriptions per 1000 patients.19 
The three UK studies to date were all small and under-
taken two decades ago. One examining 108 practices in 
Lincolnshire found higher prescribing costs and fewer 
prescriptions for generics in dispensing practices20; a 
follow-up study in the same cohort after the introduction 
of target prescribing budgets reported similar findings21; 
and a final study in the same region (with the highest 
density of dispensing practices in the country) examined 
prescription of drugs available over the counter,22 finding 
they were again more commonly prescribed in dispensing 
practices.
These papers were criticised for failing to make adequate 
adjustment for the fact that dispensing practices in rural 
areas may see different patients to urban practices; that 
dispensing practices may be required to deliver different 
services such as vaccination (which at the time was often 
not delivered in general practice); and that doctors might 
prescribe over-the-counter drugs more commonly in areas 
with no pharmacy for patients’ practical convenience. Our 
study design addresses these shortcomings. Furthermore, 
over the past two decades, there have been numerous 
developments which might affect prescribing behaviour 
including the new GP contract, the end of GP fundholding, 
Table 5 Proportion of dispensing practices in the top 10 and top 100 highest prescribers of high-cost drugs in each category
Class
% dispensing 
practices in 
top 10
% dispensing 
practices in 
top 100
% dispensing 
practices 
nationally
Mean % high 
cost in top 10
Mean % high 
cost in top 100
Mean % 
high cost in 
England
Statins 80 56 13 40.79 17.45 3.04
Proton pump inhibitor 10 11 13 33.97 11.73 1.48
ACE inhibitor 90 29 13 33.54 6.98 0.29
Angiotensin receptor blocker 100 86 13 81.42 54.64 3.90
Table 6 Modelled savings per month in England if dispensing practices prescribed drugs with the same prices as non-
dispensing practices
Drug class Savings per month Savings per year
Total annual National 
Health Service England 
spend on this class % possible savings
Statins £276 248.37 £3 314 980.44 £140 314 432 2.36
Proton pump inhibitor £33 448.80 £401 385.60 £107 035 456 0.38
Angiotensin receptor blocker £299 194.82 £3 590 337.84 £56 320 168 6.37
ACE inhibitor £19 982.77 £239 793.24 £66 674 248 0.36
Total £628 874.76 £7 546 497.12 £370 344 304 2.04
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changes in clinical evidence and the formation of the 
National Institute for Health and Care Excellence. There 
has also been extensive patent expiry and subsequent 
dramatic cost reductions for many commonly prescribed 
classes of drug, including PPIs, ARBs, ACEi and statins.
Lastly, in the grey literature, a recent analysis by the 
Dispensing Doctors Association reports that the overall cost 
of drugs supplied per patient from English dispensing prac-
tices was less than that for prescriptions dispensed in phar-
macies.23 However, this analysis uses a crude metric, makes 
no attempt to correct for confounders, does not apply the 
widely used Age, Sex and Temporary Resident Prescribing 
Unit24 as a patient denominator and is produced by the 
lobbying body for dispensing practices.
In the broader context of financial incentive and doctors’ 
clinical activity, the current Cochrane overview of reviews 
evaluating the effectiveness of financial incentives in 
changing healthcare professionals’ behaviours finds that 
overall such incentives are commonly effective.25 A negative 
impact from a perverse incentive is therefore plausible.
Meaning and policy implications
We have identified clear evidence that many doctors are 
responding to a financial conflict of interest. This has 
important implications more broadly than for dispensing 
practices, as it demonstrates that clinical decision-making 
may not be solely driven by patient need, and that unwar-
ranted variation in care may be partly driven by financial 
factors for the doctor. It may also have safety implications, 
since newer drugs with no clear evidence of superior 
clinical benefit are likely to be used less frequently, and 
so have less safety data, but are currently prescribed to a 
greater extent in dispensing practices.
We have also identified significantly higher costs asso-
ciated with dispensing practices, with a total of £7 546 
502 per year in England across these four classes of drug, 
2.04% of the total national spend on them. There are 
likely to be additional higher costs from other classes of 
drug. It may be argued that this is not avoidable waste, 
on the grounds that dispensing practices need this addi-
tional income in order to meet the higher costs associ-
ated with providing dispensing services in areas with a low 
population density. However, since most dispensing prac-
tices have not leveraged this opportunity for additional 
revenue, that seems unlikely; it is more likely that this is 
additional income for a small number of practices who 
have identified and acted on a financial opportunity in 
NHS systems for reimbursement of prescribing costs.
The NHS currently spends £13 billion per year on 
prescribed medication, representing over 10% of the 
total NHS budget. Much of this is amenable to efficiency 
savings.26 We believe that better monitoring of prescribing 
behaviour would allow easier identification of outliers on 
cost, effectiveness and safety, and that more robust action, 
when presented with outliers is likely to reduce costs and 
improve clinically effective prescribing. Some formularies 
may wish to restrict the use of very high-cost items.
Future research
We have recently received funding for a series of low-cost 
randomised trials assessing whether open audit and feed-
back on individual practices’ prescribing data changes 
prescribing practice. We strongly suggest that existing 
processes to identify and address problematic prescribing 
behaviour should be reviewed, with their costs and 
evidence base assessed.
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